摘要
目的探讨辛伐他汀对急性心肌梗死(AMI)患者血清C反应蛋白(CRP)水平及纤溶活性的影响。方法60例AMI患者随机分为常规治疗组(30例)和阿托伐他汀治疗组(30例),20例健康人为对照组。阿托伐他汀治疗组于常规治疗基础上加用辛伐他汀40g/d,疗程为4周。两组均于治疗前和治疗结束时测定血清CRP、血清总胆固醇(TC)、甘油三酯(TG)、高密度脂蛋白胆固醇(HDLC)、低密度脂蛋白胆固醇(LDLC)、组织型纤溶酶原激活物(tPA)和纤溶酶原激活物抑制物1(PAI1)。结果辛伐他汀组治疗4周后,CRP、TC、TG、LDLC、PAI1较治疗前下降(P<0.05或0.01)。常规组治疗前后无明显变化(P>0.05)。治疗前AMI患者血清CRP与PAI1活性呈正相关(r=0.393,P<0.05),与tPA呈负相关(r=-0.359,P<0.01)。辛伐他汀组治疗后CRP、PAI1、tPA与TC、LDLC水平变化无相关性。结论在AMI早期给予大剂量辛伐他汀治疗,可能有利于抑制炎症反应,稳定斑块,提高纤溶活性。
Objective To study the effect of high-dose simvastatin on fibrinolytic activity and C-reactive protein （ CRP） in patients with acute myocardial infarction （ AMI）. Methods 60 AMI cases were randomly divided into routine treatment group （ n = 30） and simvastatin treatment group （ n = 30） and 20 healthy subjects were taken as eontrols. Simvastatin treatment group took 40g/d simvastatin for 4 weeks in addition to routine therapy. CRP, serum total cholesterol （TC）, triglyceride （TG）, high-density lipoprotein cholesterol （HDL-C）, low-density lipoprotein cholesterol （LDL-C） ,tissue-type plasminogen activator （t-PA） and plasminogen activator inhibitor-1 （PAI-1） levels were measured before and after treatment. Results After 4-week treatment, the levels of CRP, TC, TG, LDL-C, and PAI-1 of simvastatin treatment group were decreased （ P〈 0.05 or 0.01 ） ,however,which were not changed sig- nificantly in routine group （ P 〉 0.05 ）. Before treatment, CRP level of AMI patients was positively correlated with PAI-1 level（ r = 0. 393, P 〈 0.05 ） and negatively correlated with t-PA level（ R = -0. 359, P 〈0.01 ）, while the simvastatin treatment group did not show any correlation of CRP,PAI-1 and t-PA levels with TC and LDL-C levels after treatment. Condttsion Early high-dose simvastatin treatment may be helpful to inhibit inflammatory responses, increase fibrinolytic activity and stabilize atherosclerotic plaque in AMI patients.
出处
《中国医药》
2006年第1期18-20,共3页
China Medicine
关键词
辛伐他汀
急性心肌梗死
C-反应蛋白
纤溶活性
Simvastatin
Acute myocardial infarction,
C-reactive protein
Fibrinolytic activity
